Chi Kong Li

Prof. Chi Kong Li

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2018 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
LCLei Cui
Lei Cui
ZLZhi‐Gang Li
Zhi‐Gang Li
YCYi‐Huan Chai
Yi‐Huan Chai
JYJie Yu
Jie Yu
JGJu Gao
Ju Gao
OGon behalf of the Chinese Children Leukemia Group(CCLG)
on behalf of the Chinese Children Leukemia Group(CCLG)

21 December 2010 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
CLChang Liu
Chang Liu
JLJianqin Li
Jianqin Li
FMFanyi Meng
Fanyi Meng
SLSimon X Liang
Simon X Liang
RDRuixia Deng
Ruixia Deng
Mo YangMo Yang
Mo Yang
Dozens of Traditional Chinese Medicine (TCM) formulas have been used for promotion of "blood production" for centuries, and we are interested in developing novel thrombopoietic medicines from these TCMs. Our previous studies have demonstrated the hematopoietic effects of DangGui BuXue Tong (DBT), a formula composed of Radix Angelicae Sinensis and Radix Astragali in animal and cellular models. As a step further to identify and characterize the active chemical components of DBT, we tested the hematopoietic and particularly, thrombopoietic effects of polysaccharide-enriched fractions from the root of Radix Angelicae Sinensis (APS) in this study.

1 February 2017 in Best Practice & Research Clinical Obstetrics & Gynaecology
Verified
Journal Article
Closed access
Chi Kong LiChi Kong Li
Chi Kong Li

8 March 2021 in Blood
Verified
Journal Article
Open access
PDF file
JTJingyan Tang
Jingyan Tang
JYJie Yu
Jie Yu
JCJiaoyang Cai
Jiaoyang Cai
LZLi Zhang
Li Zhang
SHShaoyan Hu
Shaoyan Hu
CPChing-Hon Pui
Ching-Hon Pui
To identify the prognostic factors that are useful to improve central nervous system (CNS) control in children with acute lymphoblastic leukemia (ALL), we analyzed the outcome of 7640 consecutive patients treated on Chinese Children’s Cancer Group ALL-2015 protocol between 2015 and 2019. This protocol featured prephase dexamethasone treatment before conventional remission induction and subsequent risk-directed therapy, including 16 to 22 triple intrathecal treatments, without prophylactic cranial irradiation. The 5-year event-free survival was 80.3% (95% confidence interval [CI], 78.9-81.7), and overall survival 91.1% (95% CI, 90.1-92.1). The cumulative risk of isolated CNS relapse was 1.9% (95% CI, 1.5-2.3), and any CNS relapse 2.7% (95% CI, 2.2-3.2). The isolated CNS relapse rate was significantly lower in patients with B-cell ALL (B-ALL) than in those with T-cell ALL (T-ALL) (1.6%; 95% CI, 1.2-2.0 vs 4.6%; 95% CI, 2.9-6.3; P < .001). Independent risk factors for isolated CNS relapse included male sex (hazard ratio [HR], 1.8; 95% CI, 1.1-3.0; P = .03), the presence of BCR-ABL1 fusion (HR, 3.8; 95% CI, 2.0-7.3; P < .001) in B-ALL, and presenting leukocyte count ≥50×109/L (HR, 4.3; 95% CI, 1.5-12.2; P = .007) in T-ALL. Significantly lower isolated CNS relapse was associated with the use of total intravenous anesthesia during intrathecal therapy (HR, 0.2; 95% CI, 0.04-0.7; P = .02) and flow cytometry examination of diagnostic cerebrospinal fluid (CSF) (HR, 0.2; 95% CI, 0.06-0.6; P = .006) among patients with B-ALL. Prephase dexamethasone treatment, delayed intrathecal therapy, use of total intravenous anesthesia during intrathecal therapy, and flow cytometry examination of diagnostic CSF may improve CNS control in childhood ALL. This trial was registered with the Chinese Clinical Trial Registry (ChiCTR-IPR-14005706).

1 July 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
JBJudith M. Boer
Judith M. Boer
MVMaria Grazia Valsecchi
Maria Grazia Valsecchi
FHFemke M. Hormann
Femke M. Hormann
ŽAŽeljko Antić
Željko Antić
MZMarketa Zaliova
Marketa Zaliova
RPRob Pieters
Rob Pieters

4 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
FZFen Zhang
Fen Zhang
Tao ZuoTao Zuo
Tao Zuo
YYYun Kit Yeoh
Yun Kit Yeoh
FCFrankie W. T. Cheng
Frankie W. T. Cheng
QLQin Liu
Qin Liu
SNSiew C Ng
Siew C Ng
Fecal microbiota transplant (FMT) has emerged as a potential treatment for severe colitis associated with graft-versus-host disease (GvHD) following hematopoietic stem cell transplant. Bacterial engraftment from FMT donor to recipient has been reported, however the fate of fungi and viruses after FMT remains unclear. Here we report longitudinal dynamics of the gut bacteriome, mycobiome and virome in a teenager with GvHD after receiving four doses of FMT at weekly interval. After serial FMTs, the gut bacteriome, mycobiome and virome of the patient differ from compositions before FMT with variable temporal dynamics. Diversity of the gut bacterial community increases after each FMT. Gut fungal community initially shows expansion of several species followed by a decrease in diversity after multiple FMTs. In contrast, gut virome community varies substantially over time with a stable rise in diversity. The bacterium, Corynebacterium jeikeium, and Torque teno viruses, decrease after FMTs in parallel with an increase in the relative abundance of Caudovirales bacteriophages. Collectively, FMT may simultaneously impact on the various components of the gut microbiome with distinct effects.